ENHANCED CYSTOSCOPY IMPROVES BLADDER CANCER DETECTION

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company’s initial focus is bladder cancer.

Vancouver, B.C. and Boston, MA, November 6, 2017 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) confirms that experts in the field of urology concur that one reason for the high recurrence rate after transurethral resection (TUR), is that some cancer not seen was left behind by the surgeon. Some years ago, enhanced cystoscopy was put forward as a way of identifying this unseen bladder cancer.

The uptake of enhanced cystoscopy has taken a number of years to evolve, partly because new equipment and supplies had to be purchased, as well as various procedural changes that needed to be implemented. But most significantly, many of these new procedures often require up to one hour for the physician to visualize the cancer and begin the cysto-TUR. Regardless of these impediments, enhanced cystoscopy is coming into the mainstream of treating bladder cancer. Imagin’s i/Blue Imaging System is expected to reduce the time for physicians to visualize the cancer to ten minutes.

In its recently published 2017 Annual Meeting Highlights in Bladder Cancer, the AUA (American Urological Association) stated, “… the benefits of enhanced cystoscopy were highlighted, particularly in terms of fluorescent cystoscopy, which improved cancer detection and improved recurrence-free survival.” The conclusion is that the use of photo-dynamic diagnosis increases the detection of bladder cancer.

Jim Hutchens, President and CEO of Imagin Medical stated, “These procedures are an exciting, growing market in urology; and we believe our technology will continue the trend in enhanced cystoscopy.”

About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging
technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.

For further information, contact:
Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: jhutchens@imaginmedical.com

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected, except as required under applicable securities legislation; the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.